Maxygen, (FRA:MYN) Total Assets : €62.93 Mil (As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is Maxygen, Total Assets?

Maxygen,'s Total Assets for the quarter that ended in Mar. 2013 was €62.93 Mil.

Total Assets is connected with ROA %. Maxygen,'s annualized ROA % for the quarter that ended in Mar. 2013 was -10.42%. Total Assets is also linked to Revenue through Asset Turnover. Maxygen,'s Asset Turnover for the quarter that ended in Mar. 2013 was 0.00.

Maxygen, Total Assets Historical Data

The historical data trend for Maxygen,'s Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Total Assets Chart

Maxygen, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Total Assets

Get a 7-Day Free Trial

158.03

121.59

111.12

125.12

63.41

Maxygen, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
Total Assets	Get a 7-Day Free Trial															120.61	148.77	66.53	63.41	62.93

Maxygen, Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Maxygen,'s Total Assets for the fiscal year that ended in Dec. 2012 is calculated as

Total Assets	=	Total Equity (A: Dec. 2012 )	+	Total Liabilities (A: Dec. 2012 )
	=	61.102	+	2.312
	=	63.41

Maxygen,'s Total Assets for the quarter that ended in Mar. 2013 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2013 )	+	Total Liabilities (Q: Mar. 2013 )
	=	60.677	+	2.253
	=	62.93

Maxygen, (FRA:MYN) Total Assets Explanation

Total Assets is connected with ROA %.

Maxygen,'s annualized ROA % for the quarter that ended in Mar. 2013 is

ROA %	=	Net Income (Q: Mar. 2013 )	/	( (Total Assets (Q: Dec. 2012 )	+	Total Assets (Q: Mar. 2013 ))	/ count )
	=	-6.58	/	( (63.414	+	62.93)	/ 2 )
	=	-6.58	/	63.172
	=	-10.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2013) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Maxygen,'s Asset Turnover for the quarter that ended in Mar. 2013 is

	Asset Turnover
=	Revenue (Q: Mar. 2013 )	/	( (Total Assets (Q: Dec. 2012 )	+	Total Assets (Q: Mar. 2013 ))	/ count )
=	0.002	/	( (63.414	+	62.93)	/ 2 )
=	0.002	/	63.172
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Maxygen, Total Assets Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.